Market Research Outlook on Insulin Like Growth Factor 1 - Pipeline Review, H1 2016

Insulin Like Growth Factor 1 (Mechano Growth Factor or Somatomedin-C or IGF-1) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides in depth analysis on Insulin Like Growth Factor 1 (Mechano Growth Factor or Somatomedin-C or IGF-1) targeted pipeline therapeutics.

The report provides comprehensive information on the Insulin Like Growth Factor 1 (Mechano Growth Factor or Somatomedin-C or IGF-1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Insulin Like Growth Factor 1 (Mechano Growth Factor or Somatomedin-C or IGF-1) targeted therapeutics development and features dormant and discontinued projects.

To access full report with TOC, please visit Insulin Like Growth Factor 1 (Mechano Growth Factor or Somatomedin-C or IGF-1) - Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor 1 (Mechano Growth Factor or Somatomedin-C or IGF-1)
- The report reviews Insulin Like Growth Factor 1 (Mechano Growth Factor or Somatomedin-C or IGF-1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report reviews latest news and deals related to Insulin Like Growth Factor 1 (Mechano Growth Factor or Somatomedin-C or IGF-1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

AnGes MG, Inc. Boehringer Ingelheim GmbH Digna Biotech, S.L. MedImmune, LLC

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###